What Happens To Your Telemedicine Practice If DEA Flexibilities Expire In 2027

If your practice prescribes controlled substances to patients you’ve never examined in person, you’re operating under a temporary rule, not a permanent one. That distinction matters more than most providers realize, because the flexibility your business model depends on has been renewed four times since 2023, each time with an expiration date attached. The current one runs through December 31, 2026. What happens after that is still an open question, and it’s worth understanding now rather than in December.

The Rule You’re Actually Operating Under

The underlying law here is the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, which requires a practitioner to conduct an in-person medical evaluation before prescribing a controlled substance. Ryan Haight built in a “practice of telemedicine” exception, but it was written narrowly, mainly for patients located in a hospital, clinic, or in the presence of another practitioner. It never anticipated the home-based, direct-to-patient telehealth model that most practices run on today.

During the COVID-19 public health emergency, DEA and HHS suspended the in-person requirement entirely for telemedicine prescribing. When the emergency ended, they didn’t let that flexibility lapse. Instead they’ve extended it four separate times, most recently through a rule published December 31, 2025, that keeps flexibilities in place through the end of 2026. Each extension has cited the same reason: the agencies need more time to finalize permanent regulations.

Why DEA Keeps Kicking The Can

That permanent rule already exists in draft form. DEA proposed a “Special Registrations for Telemedicine and Limited State Telemedicine Registrations” framework back in January 2025, took public comment, and has been working through it since. As of late August 2026, the final rule is sitting with the Office of Information and Regulatory Affairs for review, the last procedural step before publication. Current federal timelines point to final action around November 2026, which would leave a narrow window between publication and the December 31 expiration of the current temporary flexibilities.

That timing is the real risk. Not that DEA wants prescribing access to disappear, but that a rule finalized in November with an effective date shortly after could leave practices little runway to register, adjust workflows, and get compliant before the temporary bridge falls away.

What The Permanent Rule Would Actually Require

The proposed framework creates three distinct registration types, and it’s worth knowing which one applies to your practice before the rule is final rather than after.

A Telemedicine Prescribing Registration would let a provider prescribe Schedule III through V controlled substances without an in-person evaluation. An Advanced Telemedicine Prescribing Registration extends that authority to Schedule II substances, but only for board-certified specialists in defined categories: psychiatry, hospice care, long-term care, and pediatrics. A Telemedicine Platform Registration applies to the platforms and organizations that connect patients with prescribers, requiring disclosure of the relationships between the platform, its practitioners, and any pharmacy involved.

Each registration type carries its own $888 fee. Applicants need a physical registered address, must already hold valid authority to prescribe in the state where the patient is located, and would be required to issue every controlled substance prescription through electronic prescribing systems rather than paper or phone-in orders. None of this is exotic for a practice that already takes compliance seriously, but it’s a real administrative lift if you’re starting from zero in the weeks after the rule is published.

The Scenario Nobody Wants To Plan For

Here’s the harder question: what if the permanent rule doesn’t finalize in time, and DEA doesn’t extend the temporary flexibilities a fifth time? Nothing requires them to. If that happens, the Ryan Haight in-person evaluation requirement becomes the default again, with only its original narrow exceptions available. A practice built entirely on virtual-only relationships would suddenly need an in-person encounter on file for every patient receiving a controlled substance prescription, and the statutory workarounds, patient in a hospital, patient with another practitioner present, don’t map onto how most telehealth patients actually receive care.

This isn’t the likeliest outcome. DEA has shown a consistent pattern of extending rather than letting flexibilities lapse, and a fifth extension remains plausible if the permanent rule isn’t ready. But “likeliest” isn’t the same as “certain,” and a practice with hundreds of patients on controlled substance regimens doesn’t want to be figuring out a contingency plan the week the current authorization runs out.

What To Do Now, Not Later

Track the rule’s progress rather than assuming it’ll sort itself out. The Federal Register and DEA’s own press releases are the most reliable sources, and legal counsel who handles telehealth compliance should flag major developments as they happen. If your practice includes patients on Schedule II medications prescribed by a psychiatrist or another specialist likely to qualify for the Advanced registration, understand now whether you meet the board-certification requirements the draft rule lays out.

One requirement worth planning around regardless of which way the rule lands: a physical, registered location in the state where you’re prescribing. That’s already part of how Arizona licensing and DEA registration work today, and it’s built into the proposed permanent framework too. Providers expanding into Arizona, or already practicing here without a qualifying in-state address, should treat that piece as settled rather than waiting to see how the rest shakes out.

For telemedicine providers who need that qualified Arizona address, whether to register with DEA, enroll with Medicare, or simply meet state licensing requirements, Viva MedSuites has supported providers across the country navigating exactly this kind of regulatory transition since 2017. Telemedicine memberships start at $199 a month and include a compliant physical address without the overhead of a full clinical build-out. Learn more at vivamedsuites.com/telemedicine-az-address/ or call 480-616-2400.

John Groberg is the founder of Viva MedSuites, Arizona’s largest medical coworking community, with locations in Scottsdale and Mesa serving independent practitioners since 2017.